那格列奈单药或序贯二甲双胍治疗对初诊2型糖尿病患者血糖稳定性的影响

Effect of nateglinide or sequential treatment with metformin on glycemic stability in newly diagnosed type 2 diabetic patients

观察那格列奈单药或序贯二甲双胍治疗对初诊2型糖尿病患者血糖稳定性的影响.对34例初诊2型糖尿病患者予口服那格列奈治疗,血糖不达标者再序贯加用二甲双胍,患者分为那格列奈单药组（单药组,14例）和那格列奈序贯二甲双胍组（双药组,20例）.以HbA1C及动态血糖谱中日内平均血糖波动幅度（MAGE）联合反映患者血糖稳定性.患者治疗前及治疗3个月后检测血糖稳定性指标.经过治疗后两组MAGE、HbA1C均较治疗前明显改善（P＜0.05）.使用那格列奈单药或序贯二甲双胍治疗能有效改善初诊2型糖尿病患者的血糖稳定性.

The effect of nateglinide or sequential treatment with metformin on glycemic stability in newly diagnosed type 2 diabetes was investigated. Thirty-four cases of newly diagnosed type 2 diabetes received nateglinide therapy, or sequential treatment with metformin according to fasting and postprandial blood glucose, and were classified into isolated nateglinide therapy group（n=14） and sequentially treated with metformin group（n=20）. Glycemic stability, reflected by mean amplitude of glycemic excursions（MAGE） and HbA1C, was determined in all patients before and after therapy for three months. HbA1C and MAGE in two groups were all improved after treatment（P〈0.05）. The therapy of nateglinide alone or combined with metformin can significantly improve glycemic stability in newly diagnosed type 2 diabetes.